Literature DB >> 26250410

Preventing stem cell transplantation-associated viral infections using T-cell therapy.

Ifigeneia Tzannou1, Ann M Leen1.   

Abstract

Hematopoietic stem cell transplantation is the treatment of choice for many hematologic malignancies and genetic diseases. However, viral infections continue to account for substantial post-transplant morbidity and mortality. While antiviral drugs are available against some viruses, they are associated with significant side effects and are frequently ineffective. This review focuses on the immunotherapeutic strategies that have been used to prevent and treat infections over the past 20 years and outlines different refinements that have been introduced with the goal of moving this therapy beyond specialized academic centers.

Entities:  

Keywords:  T cells; adoptive immunotherapy; hematopoietic stem cell transplantation; viral infections

Mesh：

Year:  2015        PMID： 26250410      PMCID： PMC4575639          DOI： 10.2217/imt.15.43

Source DB:  PubMed          Journal:  Immunotherapy        ISSN： 1750-743X            Impact factor:   4.196


  107 in total

1.  Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals.

Authors:  Ann M Leen; G Doug Myers; Uluhan Sili; M Helen Huls; Heidi Weiss; Kathryn S Leung; George Carrum; Robert A Krance; Chung-Che Chang; Jeffrey J Molldrem; Adrian P Gee; Malcolm K Brenner; Helen E Heslop; Cliona M Rooney; Catherine M Bollard
Journal:  Nat Med       Date:  2006-09-24       Impact factor: 53.440

2.  Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines.

Authors:  Thomas C Wehler; Marion Nonn; Britta Brandt; Cedrik M Britten; Mark Gröne; Mariya Todorova; Irina Link; Shamsul A Khan; Ralf G Meyer; Christoph Huber; Udo F Hartwig; Wolfgang Herr
Journal:  Blood       Date:  2006-08-24       Impact factor: 22.113

3.  Reversible HLA multimers (Streptamers) for the isolation of human cytotoxic T lymphocytes functionally active against tumor- and virus-derived antigens.

Authors:  Julia Neudorfer; Burkhard Schmidt; Katharina M Huster; Florian Anderl; Matthias Schiemann; Gerd Holzapfel; Thomas Schmidt; Lothar Germeroth; Hermann Wagner; Christian Peschel; Dirk H Busch; Helga Bernhard
Journal:  J Immunol Methods       Date:  2007-01-31       Impact factor: 2.303

4.  The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies.

Authors:  Catia Traversari; Sarah Marktel; Zulma Magnani; Patrizia Mangia; Vincenzo Russo; Fabio Ciceri; Chiara Bonini; Claudio Bordignon
Journal:  Blood       Date:  2007-02-27       Impact factor: 22.113

5.  Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial.

Authors:  Tanzina Haque; Gwen M Wilkie; Marie M Jones; Craig D Higgins; Gillian Urquhart; Phoebe Wingate; David Burns; Karen McAulay; Marc Turner; Christopher Bellamy; Peter L Amlot; Deirdre Kelly; Alastair MacGilchrist; Maher K Gandhi; Anthony J Swerdlow; Dorothy H Crawford
Journal:  Blood       Date:  2007-04-27       Impact factor: 22.113

6.  Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation.

Authors:  P Comoli; S Basso; M Zecca; D Pagliara; F Baldanti; M E Bernardo; W Barberi; A Moretta; M Labirio; M Paulli; M Furione; R Maccario; F Locatelli
Journal:  Am J Transplant       Date:  2007-06       Impact factor: 8.086

7.  Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation.

Authors:  Siok-Keen Tey; Gianpietro Dotti; Cliona M Rooney; Helen E Heslop; Malcolm K Brenner
Journal:  Biol Blood Marrow Transplant       Date:  2007-05-29       Impact factor: 5.742

8.  Reconstitution of adenovirus-specific cell-mediated immunity in pediatric patients after hematopoietic stem cell transplantation.

Authors:  G D Myers; C M Bollard; M-F Wu; H Weiss; C M Rooney; H E Heslop; A M Leen
Journal:  Bone Marrow Transplant       Date:  2007-04-09       Impact factor: 5.483

9.  Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation.

Authors:  Persis J Amrolia; Giada Muccioli-Casadei; Helen Huls; Stuart Adams; April Durett; Adrian Gee; Eric Yvon; Heidi Weiss; Mark Cobbold; H Bobby Gaspar; Cliona Rooney; Ingrid Kuehnle; Victor Ghetie; John Schindler; Robert Krance; Helen E Heslop; Paul Veys; Ellen Vitetta; Malcolm K Brenner
Journal:  Blood       Date:  2006-06-01       Impact factor: 22.113

Review 10.  Cellular responses to viral infection in humans: lessons from Epstein-Barr virus.

Authors:  Andrew D Hislop; Graham S Taylor; Delphine Sauce; Alan B Rickinson
Journal:  Annu Rev Immunol       Date:  2007       Impact factor: 28.527
View more
  8 in total

1.  How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation.

Authors:  Hermann Einsele; Per Ljungman; Michael Boeckh
Journal:  Blood       Date:  2020-05-07       Impact factor: 22.113

Review 2.  The Human Virome: Implications for Clinical Practice in Transplantation Medicine.

Authors:  Susanna K Tan; David A Relman; Benjamin A Pinsky
Journal:  J Clin Microbiol       Date:  2017-07-19       Impact factor: 5.948

3.  Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation.

Authors:  Ifigeneia Tzannou; Anastasia Papadopoulou; Swati Naik; Kathryn Leung; Caridad A Martinez; Carlos A Ramos; George Carrum; Ghadir Sasa; Premal Lulla; Ayumi Watanabe; Manik Kuvalekar; Adrian P Gee; Meng-Fen Wu; Hao Liu; Bambi J Grilley; Robert A Krance; Stephen Gottschalk; Malcolm K Brenner; Cliona M Rooney; Helen E Heslop; Ann M Leen; Bilal Omer
Journal:  J Clin Oncol       Date:  2017-08-07       Impact factor: 44.544

4.  Prophylactic and therapeutic adenoviral vector-based multivirus-specific T-cell immunotherapy for transplant patients.

Authors:  Vijayendra Dasari; Andrea Schuessler; Corey Smith; Yide Wong; John J Miles; Mark J Smyth; George Ambalathingal; Ross Francis; Scott Campbell; Daniel Chambers; Rajiv Khanna
Journal:  Mol Ther Methods Clin Dev       Date:  2016-08-24       Impact factor: 6.698

Review 5.  T-Cell Manipulation Strategies to Prevent Graft-Versus-Host Disease in Haploidentical Stem Cell Transplantation.

Authors:  Jayakumar Vadakekolathu; Sergio Rutella
Journal:  Biomedicines       Date:  2017-06-21

6.  Turning the tables on cytomegalovirus: targeting viral Fc receptors by CARs containing mutated CH2-CH3 IgG spacer domains.

Authors:  Julia Proff; Charlotte U Brey; Armin Ensser; Wolfgang Holter; Manfred Lehner
Journal:  J Transl Med       Date:  2018-02-08       Impact factor: 8.440

Review 7.  Needle in a Haystack: The Naïve Repertoire as a Source of T Cell Receptors for Adoptive Therapy with Engineered T Cells.

Authors:  Elvira D'Ippolito; Karolin I Wagner; Dirk H Busch
Journal:  Int J Mol Sci       Date:  2020-11-06       Impact factor: 5.923

8.  HA-1H T-Cell Receptor Gene Transfer to Redirect Virus-Specific T Cells for Treatment of Hematological Malignancies After Allogeneic Stem Cell Transplantation: A Phase 1 Clinical Study.

Authors:  Peter van Balen; Inge Jedema; Marleen M van Loenen; Renate de Boer; H M van Egmond; Renate S Hagedoorn; Conny Hoogstaten; Sabrina A J Veld; Lois Hageman; P A G van Liempt; Jaap-Jan Zwaginga; Pauline Meij; H Veelken; J H F Falkenburg; Mirjam H M Heemskerk
Journal:  Front Immunol       Date:  2020-08-20       Impact factor: 7.561
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.